Develops therapies for cancer treatment, focusing on targeted oncology drugs and monoclonal antibodies.
Oncternal Therapeutics, Inc., headquartered in San Diego, California, is a clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapies aimed at addressing critical unmet medical needs. Since its inception, Oncternal has focused on advancing treatments for cancers through a robust clinical pipeline. Key candidates include zilovertamab, a humanized monoclonal antibody targeting receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1), and ONCT-216, a small molecule designed to inhibit ETS-family transcription factor oncoproteins.
The company is also actively developing ONCT-808, a promising chimeric antigen receptor T-cell (CAR-T) therapy directed against ROR1, and ONCT-534, a dual-action inhibitor of the androgen receptor intended for treating castration-resistant prostate cancer and other cancers driven by androgen receptor signaling. Oncternal Therapeutics collaborates extensively through license agreements with prestigious institutions such as the University of California, Georgetown University, and MD Anderson Cancer Center, as well as with industry partners like Shanghai Pharmaceutical (USA) Inc. and the University of Tennessee Research Foundation.
In addition to its internal research initiatives, Oncternal Therapeutics has established a research collaboration with Celularity Inc. to explore placental-derived cellular therapies targeting ROR1. This partnership underscores Oncternal's commitment to leveraging innovative scientific approaches and strategic collaborations to advance novel cancer treatments. With a dedicated focus on advancing therapies that target specific molecular pathways, Oncternal Therapeutics continues to drive forward in its mission to transform cancer care and improve patient outcomes worldwide.